1
00:00:00,000 --> 00:00:05,875
Orforglipron shows why a receptor target and a molecule type are different things.

2
00:00:05,875 --> 00:00:10,958
It acts at the GLP-1 receptor but is a non-peptide molecule.

3
00:00:10,958 --> 00:00:17,625
In April 2026, FDA approved the tablet product Foundayo for weight management in specified adults,

4
00:00:17,625 --> 00:00:21,125
alongside reduced-calorie eating and increased physical activity.

5
00:00:21,125 --> 00:00:25,000
The approval relied on two randomized, placebo-controlled trials.

6
00:00:25,000 --> 00:00:30,875
Weight reduction was greater with treatment, while gastrointestinal side effects and other warnings

7
00:00:30,875 --> 00:00:34,375
remained part of the evaluation.

8
00:00:34,375 --> 00:00:38,625
The evidence belongs to the reviewed product and indication.

9
00:00:38,625 --> 00:00:45,708
Sharing a receptor target does not make drugs interchangeable, and an approved tablet does not validate

10
00:00:45,708 --> 00:00:49,208
unrelated research material.